Medical Device Regulation

The Medical Device Regulation (MDR), Regulation (EU) 2017/745, is a comprehensive legal framework that has been fully applicable since May 26, 2021, replacing the former Medical Device Directive (MDD). Its origin lies in the need to modernize regulations, address technological advancements like AI, and enhance patient safety across the EU. The core concept is to establish a robust, transparent, and sustainable regulatory system for the entire lifecycle of medical devices. For enterprise risk management, MDR mandates a risk management system compliant with ISO 14971. It classifies devices into four risk classes (I, IIa, IIb, III) based on their intended purpose, with stricter requirements for higher-risk devices. For AI-based medical devices, the MDR applies alongside the EU AI Act, ensuring both medical safety and specific AI-related risks are managed.

Practical application of MDR in enterprise risk management involves three key steps. Step 1: Qualification and Classification. The manufacturer must first determine if their product, especially software, qualifies as a medical device under MDR Article 2(1) and then classify it according to the rules in Annex VIII. Step 2: Implement a Quality and Risk Management System. This requires establishing a Quality Management System (QMS) compliant with ISO 13485 and a risk management process aligned with ISO 14971. This process must be documented in a risk management file. Step 3: Conduct Clinical Evaluation and Post-Market Surveillance (PMS). A thorough clinical evaluation as per Article 61 is required to demonstrate safety and performance. Post-launch, a proactive PMS system (Article 83) must be in place to continuously monitor the device. For example, a global MedTech company reduced post-market adverse event reports by over 30% after implementing a robust MDR-compliant PMS, leading to improved patient outcomes and reduced recall costs.

Taiwanese enterprises face three primary challenges with MDR implementation. First, the increased stringency of technical documentation and clinical evidence requirements is a significant hurdle, especially for SMEs. For AI/SaMD, this includes complex validation of algorithms and cybersecurity measures (e.g., per IEC 62304). Second, the scarcity of Notified Bodies designated under MDR creates a bottleneck, leading to long review timelines (12+ months) and high costs, delaying market entry. Third, there is often a lack of integrated, cross-functional expertise combining regulatory affairs, quality, clinical, and software engineering. To mitigate these, enterprises should prioritize early-stage gap analysis, partner with experienced consultants to navigate the Notified Body engagement process, and invest in building internal capacity and digital QMS tools. A key action is to start the compliance journey at the design phase, not as an afterthought.

Winners Consulting specializes in Medical Device Regulation for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact